30069-31-9

Basic information

• Product Name: N-(3-amino-4-methylphenyl)-3-(trifluoromethyl)benzamide
• Synonyms: N-(3-amino-4-methylphenyl)-3-(trifluoromethyl)benzamide
• CAS NO: 30069-31-9
• Molecular Formula: C₁₅H₁₃F₃N₂O
• Molecular Weight: 294.2717296
• Mol File: 30069-31-9.mol
• Article Data: 27

Chemical Properties

• Boiling Point: 338.4±42.0 °C(Predicted)
• Appearance: /
• Density: 1.335±0.06 g/cm3(Predicted)
• PKA: 12.88±0.70(Predicted)
• CAS DataBase Reference: N-(3-amino-4-methylphenyl)-3-(trifluoromethyl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-amino-4-methylphenyl)-3-(trifluoromethyl)benzamide(30069-31-9)
• EPA Substance Registry System: N-(3-amino-4-methylphenyl)-3-(trifluoromethyl)benzamide(30069-31-9)

Safety Data

• Hazardous Substances Data: 30069-31-9(Hazardous Substances Data)

Upstream product

• 2251-65-2 3-(Trifluoromethyl)benzoyl chloride 
• 119-32-4 4-Methyl-3-nitroanilin 
• 89-58-7 mononitro-p-xylene 
• 454-92-2 3-(trifluoromethyl)benzoic acid 
• 221876-21-7 N-(4-methyl-3-nitrophenyl)-3-(trifluoromethyl)benzamide 

Downstream Products

• 221876-21-7 N-(4-methyl-3-nitrophenyl)-3-(trifluoromethyl)benzamide 
• 221875-75-8 N-[2-methyl-5-(3-trifluoromethylbenzamido)phenyl]-3,4-dimethoxybenzamide 
• 1070908-62-1 2-chloro-benzothiazole-6-carboxylic acid [2-methyl-5-(3-trifluoromethyl-benzoylamino)-phenyl]-amide 
• 1028330-33-7 C₂₅H₂₂F₃N₅O₃ 
• 1351237-70-1 7-amino-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)thieno[2,3-b]pyrazine-6-carboxamide 
• 1351238-46-4 2-chloro-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)thieno[2,3-b]pyrazine-6-carboxamide 
• 1351237-69-8 N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-2-(pyridin-3-yl)thieno[2,3-b]pyrazine-6-carboxamide 
• 2095849-04-8 5-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)nicotinamide 

Relevant articles and documents

Evaluation of carbon-11 labeled 5-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)nicotinamide as PET tracer for imaging of CSF-1R expression in the brain

Pharmacological targeting of tumor associated macrophages and microglia in the tumor microenvironment is a novel therapeutic strategy in the treatment of glioblastoma multiforme. As such, the colony stimulating factor-1 receptor (CSF-1R) has been identified as a druggable target. However, no validated companion diagnostic marker for these therapies exists to date. Towards development of a CSF-1R PET tracer, a set of six compounds based on recently reported CSF-1R inhibitor 5-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)nicotinamide (Compound 5) was designed, synthesized and evaluated in vitro for potency and selectivity. The highest affinity for CSF-1R was found for compound 5 (IC50: 2.7 nM). Subsequent radiosynthesis of [11C]5 was achieved in 2.0 ± 0.2% yield (decay corrected to start of synthesis) by carbon-11 carbon monoxide aminocarbonylation in 40 min after end of bombardment. In vitro autoradiography with [11C]5 on rat brain sections demonstrated high specific binding, but also strong off-target binding. Ex vivo, only intact tracer was observed in blood plasma at 90 min post injection in healthy rats. PET scanning results demonstrated negligible brain uptake under baseline conditions and this brain uptake did not increase by blocking of efflux transporters using Tariquidar. To conclude, [11C]5 was successfully synthesized and evaluated in healthy rats. However, the inability of [11C]5 to cross the blood-brain-barrier excludes its use for imaging of CSF-1R expression in the brain.

DUAL SRC/P38 KINASE INHIBITOR COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS

Dual Src/p38 kinase inhibitor compounds and compositions comprising the same are disclosed. Methods of using the compounds in the treatment of hyperproliferative disease such as cancer are also disclosed.

ISOQUINOLINE-5-CARBOXAMIDE DERIVATIVE HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE

A compound selected from the group consisting of an isoquinoline-5-carboxamide derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate and a solvate thereof is effective for the prevention or treatment of diseases associated with abnormal cell growth, which are caused by abnormal activation of a protein kinases.